These 4-year follow up data from the randomized, phase II SECOMBIT trial continue to demonstrate meaningful survival benefit with immunotherapy with or without an 8-week course of targeted therapy for the first-line treatment of BRAF-mutant metastatic melanoma. Here, BRAF is linked to metastatic melanoma.